About the Journal

Focus and Scope

Open Access Macedonian Journal of Medical Sciences (OAMJMS) [formerly known as Macedonian Journal of Medical Sciences] is a top-tier open access medical science journal published by the Scientific Foundation SPIROSKI, Rajko Zhinzifov No 48, 1000 Skopje, Republic of Macedonia. OAMJMS is an international, modern, general medical journal covering all areas in the medical sciences, from basic studies to large clinical trials and cost-effectiveness analyses. We publish mostly human studies that substantially enhance our understanding of disease epidemiology, etiology, and physiology; the development of prognostic and diagnostic technologies; trials that test the efficacy of specific interventions and those that compare different treatments; and systematic reviews. We aim to promote translation of basic research into clinical investigation, and of clinical evidence into practice. We publish occasional studies in animal models when they report outstanding research findings that are highly clinically relevant. Our audience is the international medical community as well as educators, policy makers, patient advocacy groups, and interested members of the public around the world. OAMJMS is published continuously online version.

The Open Access Macedonian Journal of Medical Sciences (OAMJMS) publishes Medical Informatics, Basic Science, Clinical Science, Case Report, Brief Communication, Public Health, Public Policy, and Review Article from all fields of medicine and related fields.

This journal also publishes, continuously or occasionally, the bibliographies of the members of the Society, medical history, medical publications, thesis abstracts, book reviews, reports on meetings, i­n­formation on future meetings, important events and dates, and various headings which contribute to the development of the corresponding scientific field.


Peer Review Process



The Reviewer is invited by email to review a submission, which includes its title and abstract, as well as the journal's URL and a username and password for the Reviewer to use to enter the journal. The journal has the option of using a reviewer option that sends the submission as an email attachment to the Reviewer along with an invitation to review. In this case, the Reviewer then responds by email <link>. What is described here is the principal method for reviewing (and ensuring complete records of the process), which involves the Reviewer conducting the Review on the journal's web site.

More details can be found in Chapter 15: Reviewing


Open Access Policy

Open Access Macedonian Journal of Medical Sciences (OAMJMS) endorses the definition of open access publication drafted by the Bethesda Meeting on Open Access Publishing. However, OAMJMS has chosen to apply the less-restrictive Creative Commons Attribution License (CCAL) to all works we publish. Unlike the Bethesda Convention, the CCAL allows commercial re-use of all OAMJMS journals' content.

An Open Access Publication[1] is one that meets the following two conditions:

  1. The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship,[2] as well as the right to make small numbers of printed copies for their personal use.

  2. A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving (for the biomedical sciences, PubMed Central is such a repository).

[1] Open access is a property of individual works, not necessarily journals or publishers.

[2] Community standards, rather than copyright law, will continue to provide the mechanism for enforcement of proper attribution and responsible use of the published work, as they do now.

Bibliographic Information

Journal Title: Open Access Macedonian Journal of Medical Sciences
Journal Initials: OAMJMS
Journal Abbreviation: Open Access Maced J Med Sci
eISSN: 1857-9655
DOI: 10.3889/oamjms
Frequency: Continuously
Article ID: 1+
Publisher: Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
History: 2013+
URL: http://www.id-press.eu/mjms/index/

Similarity Check Plagiarism Screening System


What is Similarity Check?

Similarity Check powered by iThenticate is an initiative started by Crossref to help its members actively engage in efforts to prevent scholarly and professional plagiarism. Although there are several plagiarism screening tools already available, they are not well-suited to filtering academic content simply because they haven't had access to the relevant full-text literature to screen against. Similarity Check changes this by creating and continuously growing a database of current and archival scholarly literature.
This database is one of two parts that make up the Similarity Check service. The second part is the 
iThenticate  tool, which compares authored work against the content in the database and highlight matching or similar text for further editorial review.

- See more at: http://www.crossref.org/crosscheck/index.html#sthash.YTbPBs25.dpuf


Scientific Foundation SPIROSKI Similarity Check Plagiarism Screening System  

The Editors and Boards of Open Access Macedonian Journal of Medical Sciences are participating in a growing community of Similarity Check System’s users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process.


ID Design 2012 uses the iThenticate software to detect instances of overlapping and similar text in submitted manuscripts in all journals published by ID Design 2012. Wherever you see the “Similarity Check Deposited” or “Similarity Check Depositor” logos, you can be reassured that the publisher whose content you are reading is committed to actively combating plagiarism and publishing original research. View ID Design 2012’s plagiarism policy here. To find out more about Similarity Check visit http://www.crossref.org/crosscheck/index.html

CrossMark Policy Statement


CrossMark Support

CrossMark is a multi-publisher initiative to provide a standard way for readers to locate the current version of a piece of content. By applying the CrossMark logo Id Design 2012/DOOEL Skopje is committing to maintaining the content it publishes and to alerting readers to changes if and when they occur.
Clicking on the CrossMark logo will tell you the current status of a document and may also give you additional publication record information about the document.

- See more at: http://www.crossref.org/crossmark/PublishersPolicy.htm#sthash.oQXmDn1q.dpuf

- See CrossMark® for Researchers at: http://www.crossref.org/crossmark/Researchers.htm



Scientific Foundation SPIROSKI CrossMark Policy Statement  

Scientific Foundation SPIROSKI that will have the CrossMark icon is restricted to current and future journal content and limited to specific publication types (see below) and only on contents hosted by official Scientific Foundation SPIROSKI websites. 


Publication types:

Article Type

Short Description


Abstract of a paper or oral presentation or poster, published as a separate item. A better name would be “extra short communication”. These mostly occur in fairly great numbers in conference proceedings, where not all authors are allowed to publish a full-length article.


Publication item giving additional information regarding another publication item, mostly presenting additional results.

Case Report

Used in medical literature: A detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient.


Letter to the editor or a reply to the letter.


Accidental duplication of an article in another journal. The text of the article is retracted. The HTML pages are replaced by a single page with citation details and an explanation. The PDF pages remain with a watermark on every page to notify it is a duplicate.


Article in which errors are reported that were made in an earlier publication in the same journal. Can be Erratum (publishing error) but also Corrigendum (author error).

Full Length Article

Complete report on original research.

Practice Guidelines

Text described recommended best practice in medical articles.


The text of the article is removed. The HTML pages and PDF pages of the article are completely removed and replaced by a single page with citation details and an explanation.


The text of the article is retracted. The HTML pages are replaced by a single page with citation details and an explanation. The PDF pages remain with a watermark on every page to notify it is retracted.

Review article

Substantial overview of original research, usually with a comprehensive bibliography, generally also containing a table of contents.

Short Communication

Short report or announcement of research, usually claiming certain results, usually with a shorter publication time than other papers in the same publication. Appear under many names, such as Letter Papers, Preliminary notes, Notes, etc.

Short Review

Short or mini-review.

There are 12 defined types of accepted “update” within CrossMark. The values for these are:

  • addendum

  • clarification

  • correction

  • corrigendum

  • erratum

  • expression_of_concern

  • new_edition

  • new_version

  • partial_retraction

  • removal

  • retraction

  • withdrawal


We follow COPE Guidelines for Retracting Articles (pdf).

Minor errors that do not affect the integrity of the metadata or a reader's ability to understand an article and that do not involve a scientific error or omission will be corrected at the discretion of the publisher. In such a case, the original article is removed and replaced with a corrected version. The date the correction is made is noted on the corrected article.

Editorial & Publishing Policies as well as Guidelines to Scientific Foundation SPIROSKI journals  are available on each journal site. All of Scientific Foundation SPIROSKI's journals can be found here.

The following guideline may also be helpful:

Cited-by Linking



Crossref Cited-by Linking (formerly Forward Linking) is a service that allows you to discover how your publications are being cited and to incorporate that information into your online publication platform. Participation in Crossref Cited-by Linking is entirely optional and there is no charge for it, but in order to participate, there is an important quid-pro-quo: in order to discover what publications cite your content, you must in turn submit metadata listing the works that your publications cite.

- See more at: http://www.crossref.org/citedby/index.html#policies

In practice, this is not hard to do. Reference metadata can be easily included within normal batch DOI deposits, and it is now even possible to deposit references for Cited-by Linking through the cut-and-paste Simple Text Query interface.

But, as is the case with all Crossref initiatives, the utility of Cited-by Linking is directly proportional to the uptake of the membership and, although Crossref staff actively promotes Cited-by Linking to its membership through webinars and email reminders, participation in the service has been limited. This, in turn, means that the utility of the "Cited By" information varies greatly across disciplines and publishers.

Although there are other services that provide cited-by facilities (e.g. Google Scholar, Scopus, ISI and some hosting providers.), we think that Crossref Cited-by Linking complements these other services because:

  • It is controlled and managed by the Crossref membership. As such, it enables direct primary publisher-to-publisher linking without the use of intermediaries.
  • It is not tied to any particular "metric", although the metadata provided by the service could be used by others to either validate existing metrics or as the foundation for creating new metrics.
  • It is not constrained by discipline and, as such, will prove useful for discovery of otherwise hard-to-find interdisciplinary citations and for use by publishers in fields that are underserved by the other services.
  • It is not constrained by content type. Crossref can accept reference data for journals articles, monographs, reference works, etc.

The Crossref Cited-by Linking service is built on top of the DOI infrastructure and, as such, is very precise.
Crossref is increasingly being looked to as a source for collecting authoritative publisher metadata. We are finding that those who seek to use Crossref's metadata services are increasingly interested in collecting reference metadata as well. We worry that, if they can not get citation metadata from us, they will resort to using the much less accurate metadata that they can gather through screen scraping and services like Google Scholar.
Note: Because this is an optional service for our members and only a subset of the membership is currently participating, you will only be able to retrieve a partial list of the DOIs that actually cite your content. Crossref cited-by links are not intended for use as a citation metric.

Editorial and Publishing Policies

1. Relationship to other Macedonian Medical Journals

Open Access Macedonian Journal of Medical Sciences (OAMJMS) publish outstanding research articles in health and biological sciences. Several other medical journals (Makedon Med Pregl, God Zb Med Fak Skopje, Maked J Med, Prilozi, Acta Chir Maced, Acta Morphol, and Physioacta) are published in the Republic of Macedonia.  Each journal has a team of professional and academic editors evaluating papers for publication. Occasionally, a manuscript is submitted that falls on the border between basic and clinical research or is classified as a professional paper. To ensure that such papers receive the fairest possible treatment, the professional editors of other medical journals may consult each other on relevant manuscripts. As a result, authors who have submitted their manuscript to OAMJMS may be encouraged instead to submit their paper to other medical journals (and vice versa). However, papers will never be transferred between the journals without an author's consent.

Authors may request or editors may suggest that papers or presubmission enquiries (with reviews, if relevant) rejected from OAMJMS be forwarded to an appropriate other Macedonian medical journal, for further consideration. Editorial staff at OAMJMS will help with transferring papers.


2. Publication Charges

To provide open access, OAMJMS use a business model in which our expenses—including those of peer review, journal production, and online hosting and archiving—are recovered in part by charging a subscription fee to the institutions or research sponsors. Editors and reviewers have no access to payment information, and hence inability to pay will not influence the decision to publish a paper. For further information, see ourSubscriptions and Sponsors.


3. Copyright and License Policies

Upon submission of an article, authors are asked to indicate their agreement to abide by an open-access license. The license permits any user to download, print out, extract, archive, and distribute the article, so long as appropriate credit is given to the authors and source of the work. The license ensures that your article will be as widely available as possible and that your article can be included in any scientific archive.

Upon publication, OAMJMS also intend to deposit all articles in PubMed Central. This complies with the policies of funding agencies, such as theNIH in the USA, the Wellcome Trust and the Research Councils in the UK, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases. Please read about the Open Access License before submitting your paper.


4. Human and Animal Research

All research involving humans and animals must have been approved by the authors’ institutional review board or equivalent committee, and that board must be named by the authors. In the case of human participants, informed consent must have been obtained, and all clinical investigation must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should submit a statement from the ethics committee or institutional review board indicating approval of the research. We also encourage authors to submit a sample of a patient consent form, and may require submission on particular occasions.

For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should, as much as possible,

  • make explicit their methods of categorizing human populations;

  • define categories in as much detail as the study protocol allows;

  • justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency;

  • explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, etc.

In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: "Caucasian" should be changed to "white" or "of [Western] European descent" (as appropriate); "cancer victims" should be changed to "patients with cancer".


5. Author Status

OAMJMS follows the guidelines of the International Committee of Medical Journal Editors on authorship, and authors should make sure they are familiar with these guidelines. All authors will be contacted via e-mail at submission by the OAMJMS editorial office to indicate that they are aware of and approve the submission to OAMJMS of the manuscript, its content, authorship, and order of authorship. No decision can be made on an article until all authors have provided their assent to publication. The involvement of any professional medical writer in publication must be declared. We encourage authors to consult the European Medical Writers’ Association Guidelines on the role of medical writers.


6. Competing Interests

Authors are asked at submission to declare whether they have any financial, personal, or professional interests that could be construed to have influenced their paper. Reviewers are also asked to declare any interests that might interfere with their objective assessment of a manuscript. Any relevant competing interests of authors must be available to editors and reviewers during the review process and will be stated in published articles. Click here for more general information on the OAMJMS’s policy regarding competing interests.


7. Submission of Related Manuscripts

When submitting an article, all authors are asked to indicate that they have not submitted a similar manuscript for publication elsewhere. If related work has been submitted elsewhere, then a copy must be included with the article submitted to OAMJMS. Reviewers will be asked to comment on the overlap between related submissions.


8. Reviewer and Editor Exclusions

Upon submission of a manuscript, authors are asked if they wish to include or exclude any specific academic editors or reviewers from the peer review of their article. The editorial team will respect these requests so long as this does not interfere with the objective and thorough assessment of the article. See the relevant guidelines for reviewers and more general information on OAMJMS’ policy regarding competing interests.


9. Confidentiality

Editors and reviewers are requested to treat all submitted manuscripts in strict confidence.


10. Blogs, Wikis, Embargoes and the Media

Authors are of course at liberty to present and discuss their findings ahead of publication: at medical or scientific conferences, on preprint servers, in public databases, and in blogs, wikis and other informal communication channels. We recommend, however, that authors not contact the media or respond to such contact unless an article has been accepted for publication and an embargo date has been established. Respect for press embargoes will help to ensure that your work is reported accurately in the popular media, and that the full peer-reviewed paper is freely available to any interested reader when the news item is published. If a journalist has covered a piece of work ahead of publication, this will not affect consideration of the work for publication.


11. Scientific and Editorial Misconduct

Scientific misconduct is defined by the Office of Research Integrity as "fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the academic community for proposing, conducting, or reporting research." In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in manuscripts submitted for review, OAMJMS reserves the right to pass along these manuscripts to the sponsoring or funding institution or other appropriate authority for investigation. Although OAMJMS recognizes its responsibility to ensure that the suspicion of misconduct has been addressed, we do not ourselves make such determinations. OAMJMS is also represented at the Committee on Publication Ethics (COPE) and will abide by its principles and rulings.


12. Corrections and Additions

Corrections to articles will be considered for publication if the correction is judged by the editors to affect seriously the interpretation of the work and if all authors of the original publication have approved the correction. In cases of a dispute, authors should contact the editors. Authors should send corrections directly to the journal editorial staff.


13. Sharing of Materials, Methods, and Data

Publication is conditional upon the agreement of authors to make freely available any materials and information associated with their publication that are reasonably requested by others for the purpose of academic, noncommercial research.

Data Availability

Open access applies to both the scientific literature and the data used to establish that literature. Publication is contingent on making data integral to a manuscript freely available without restriction, provided that appropriate attribution is given and that suitable mechanisms exist for sharing the data used in a manuscript and that in the case of clinical information patient confidentiality is not compromised.

  1. Data for which public repositories have been established that are in general use should be deposited before publication, and the appropriate accession numbers or digital object identifiers published with the paper.

  2. If an appropriate repository does not exist, data should be provided as supporting information with the published paper. If this is not practical, data should be made freely available upon reasonable request.

  3. The conclusions of a study must not be dependent solely on the analysis of proprietary data. If proprietary data were used to reach a conclusion, and the authors are unwilling or unable to make these data public, then the paper must include an analysis of public data that validates the conclusions so that others can reproduce the analysis and build on the findings.

Note that any restrictions on the availability or on the use of datasets might be judged to diminish the significance of a paper and will therefore influence the decision about whether a paper should be published. These policies have been developed in accordance with the principles established in Sharing Publication-Related Data and Materials (National Academies Press, 2003).

Software/Algorithm Sharing

If new software or a new algorithm is central to a paper, the authors must provide sufficient information to allow interested users to reproduce and build on the authors’ work. In cases where the software/algorithm is not central to the paper, we nevertheless encourage authors to make all relevant materials freely available. Software can be provided under license where necessary, but any restrictions on the availability or on the use of materials might be judged to diminish the significance of a paper and therefore might influence the decision about whether a paper should be published subject to those conditions. These policies have been developed in accordance with the principles established in Sharing Publication-Related Data and Materials (National Academies Press, 2003).


14. Nomenclature

The use of standardized nomenclature in all fields of science and medicine is an essential step toward the integration and linking of scientific information reported in published literature. We will enforce the use of correct and established nomenclature wherever possible:

  • We strongly encourage the use of SI units. If you do not use these exclusively, please provide the SI value in parentheses after each value.

  • Species names should be italicized (e.g., Homo sapiens) and the full genus and species must be written out in full, both in the title of the manuscript and at the first mention of an organism in a paper; after that, the first letter of the genus name, followed by the full species name may be used.

  • Genes, mutations, genotypes, and alleles should be indicated in italics. Use the recommended name by consulting the appropriate genetic nomenclature database, e.g., HUGO for human genes. It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman: v-fes, c-MYC, etc.

  • The Recommended International Non-Proprietary Name (rINN) of drugs should be provided.


15. Reporting Guidelines for Specific Study Designs

a. Clinical Trials

We follow the WHO definition of a clinical trial. See http://www.who.int/ictrp/en/.

"A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc"

MJMS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration. All trials initiated after 1 July 2005 must be registered prospectively in a publicly accessible registry (i.e., before patient recruitment has begun), or they will not be considered for publication. For trials initiated before 1 July 2005, all trials must be registered before submission to our journals. See the ICMJE faq on trial registration for further details. The WHO's list of approved registries is listed here.

Authors of trials must adhere to the CONSORT reporting guidelines appropriate to their trial design. Please check the CONSORT statement web site for information on the appropriate guidelines for specific trial types. Before the paper can enter peer review authors must: 1) name in the paper trial registry, trial registration number, and IRB and 2) provide a copy of the trial protocol and a completed CONSORT checklist as supporting files (these documents will also be published alongside the paper, if accepted). The CONSORT flow diagram must be included as Figure 1. Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and MJMSreserves the right to ask for a copy of the patient consent form. Information on statistical methods or participants beyond what is indicated in the CONSORT statement should be reported in the Methods section.

OAMJMS supports the public disclosure of all clinical trial results, as mandated for example by the FDA Amendments Act, 2007. Prior disclosure of results on a public website such as clinicaltrials.gov will not affect the decision to peer review or acceptance of papers in OAMJMS.

b. Systematic Reviews and Meta-Analyses of Randomized Controlled Trials

Reports of meta-analyses of randomized controlled studies should use the QUOROM statement as a guide (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF [1999] Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. Lancet354: 1896–900), and should include a copy of the QUOROM checklist.

c. Diagnostic Studies

Reports of studies of diagnostic accuracy should conform to the STARD requirements.

d. Epidemiological Studies

For reports of epidemiological studies, you should consult the STROBE initiative.

e. Microarray Experiments

Reports of microarray experiments should conform to the MIAME guidelines, and the data from the experiments must be deposited in a publicly accessible database.


16. Publication of Studies Sponsored by Pharmaceutical Companies.

We support the development of guidelines for the reporting of studies sponsored by pharmaceutical companies.

Competing Interests Policy

What Is a Competing Interest?

A competing interest for a scholarly journal is anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, review, or publication of research findings, or of articles that comment on or review research findings. Competing interests can be financial, professional, or personal; hidden or declared; actual or perceived.

Competing interests can be held by authors, their employer (whether academic institution, commercial company, or other), sponsors of the work, reviewers, and editors. They can arise in a relationship with an organization or another person.



The Open Access Macedonian Journal of Medical Sciences (OAMJMS) is committed to making all scientific and medical research freely accessible; it is equally important to ensure that the research is as free from bias as possible, and is seen to be so.

The editors of a OAMJMS may decide not to publish papers, either original research articles or any others, when we believe the competing interests are such that they may have compromised the work or the analyses or interpretations presented in the paper.



Authors must declare to the editors of OAMJMS all competing interests with people or organizations that might reasonably be perceived as relevant and that arose within five years of the commencement of the work described or, if not original research, of the article being written. The editors will make the final decision, if necessary after discussion with peer reviewers, about whether any declared competing interests are likely to have substantially compromised the work. No decision on papers submitted to OAMJMS will be made until the competing interests of all authors are declared. We will publish all relevant positive and negative statements of competing interests.

Examples of competing interests include, but are not limited to:

  • Financial

    • Stock ownership

    • Paid employment

    • Board membership

    • Patent applications (pending or actual)

    • Research grants (from whatever source)

    • Travel grants and honoraria for speaking or participation at meetings

    • Gifts

  • Personal

    • Membership of lobbying organizations

    • Relationship with editors, or the editorial board of a OAMJMS, or with possible reviewers of the paper

  • Professional

    • Acting as an expert witness

    • Membership of a government advisory board

    • Relationship with organizations and funding bodies

    • Writing for an educational company

If authors know that organizations or institutions that have provided support for the work or for authors' salaries have received any grants from other institutions or companies that have been involved or have an interest in the work described, such information should be declared. Institutions should also declare any relevant patents, both pending and actual. The role of all funding sources in the work should be described, including whether they were involved in the decision to submit the manuscript for publication.



Reviewers should consider whether any of the above applies to them and declare any such competing interests. If they feel they cannot review a paper because of such a competing interest, they should tell us. They should also declare any association with the authors of a paper.



Both professional and academic editors should consider whether any of the above competing interests are relevant to them and the manuscript under consideration. If so, they should decline to handle the paper.

Principles of Transparency and Best Practice in OAMJMS

<td wi

Content defined by DOAJ [https://doaj.org/bestpractice]

Applied by OAMJMS [http://www.id-press.eu/mjms/index]

1. Peer review process

Journal content must be clearly marked as whether peer reviewed or not. Peer review is defined as obtaining advice on individual manuscripts from reviewers expert in the field who are not part of the journal's editorial staff. This process, as well as any policies related to the journal’s peer review procedures, shall be clearly described on the journal's Web site.


2. Governing Body

Journals shall have editorial boards or other governing bodies whose members are recognized experts in the subject areas included within the journal's scope. The full names and affiliations of the journal's editors shall be provided on the journal's Web site.


3. Editorial team/contact information

Journals shall provide the full names and affiliations of the journal's editors on the journal's Web site as well as contact information for the editorial office.


4. Author fees

Any fees or charges that are required for manuscript processing and/or publishing materials in the journal shall be clearly stated in a place that is easy for potential authors to find prior to submitting their manuscripts for review or explained to authors before they begin preparing their manuscript for submission.


5. Copyright

Copyright and licensing information shall be clearly described on the journal's Web site, and licensing terms shall be indicated on all published articles, both HTML and PDFs.


6. Identification of and dealing with allegations of research misconduct

Publishers and editors shall take reasonable steps to identify and prevent the publication of papers where research misconduct has occurred, including plagiarism, citation manipulation, and data falsification/fabrication, among others. In no case shall a journal or its editors encourage such misconduct, or knowingly allow such misconduct to take place. In the event that a journal's publisher or editors are made aware of any allegation of research misconduct relating to a published article in their journal - the publisher or editor shall follow COPE's guidelines (or equivalent) in dealing with allegations.


7. Ownership and management

Information about the ownership and/or management of a journal shall be clearly indicated on the journal's Web site. Publishers shall not use organizational or journal names that would mislead potential authors and editors ´ about the nature of the journal's owner.


8. Web site

A journal's Web site, including the text that it contains, shall demonstrate that care has been taken to ensure high ethical and professional standards. It must not contain misleading information, including any attempt to mimic another journal/publisher's site.


9. Name of Journal

The Journal name shall be unique and not be one that is easily confused with another journal or that might mislead potential authors and readers about the Journal's origin or association with other journals.

Original name (no similar name in the world)

10. Conflicts of interest

A journal shall have clear policies on handling potential conflicts of interest of editors, authors, and reviewers and the policies should be clearly stated.


11. Access

The way(s) in which the journal and individual articles are available to readers and whether there are associated subscription or pay per view fees shall be stated.


12. Revenue sources

Business models or revenue sources (eg, author fees, subscriptions, advertising, reprints, institutional support, and organizational support) shall be clearly stated or otherwise evident on the journal's Web site.


13. Advertising

Journals shall state their advertising policy if relevant, including what types of ads will be considered, who makes decisions regarding accepting ads and whether they are linked to content or reader behavior (online only) or are displayed at random.


14. Publishing schedule

The periodicity at which a journal publishes shall be clearly indicated.


15. Archiving

A journal's plan for electronic backup and preservation of access to the journal content (for example, access to main articles via CLOCKSS or PubMedCentral) in the event a journal is no longer published shall be clearly indicated.

PubMed Central
Europe PMC

16. Direct marketing


Published by

About us



About the Journal

Editorial Team

Author Fees

Online Payments

Bibliographic Information

Journal History

For readers

For authors

For librarians

For Reviewers



Co publisher



Privacy statement